Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression
MCL1-High BTCs are sensitive to CDK2/9 inhibition and benefit from combination with PARP inhibitor. In MCL1-Low BTCs, combining CDK2/9 inhibitor and BRD4 inhibitor may represent an optimal strategy for new drug development.
Authors
- Sea Young Choo
- Kyoung-Seok Oh
- Do‐Youn Oh (ORCID: https://orcid.org/0000-0003-1663-9901)
- Hyo Jung Kim (ORCID: https://orcid.org/0000-0001-7644-2233)
- Ah‐Rong Nam
- Jae‐Min Kim (ORCID: https://orcid.org/0000-0003-4154-0612)
- Tae‐Yong Kim (ORCID: https://orcid.org/0000-0002-3930-6766)
- Jeesun Yoon (ORCID: https://orcid.org/0000-0002-1456-2392)
- Yoojin Jeong
- Ju‐Hee Bang
- Su In Lee (ORCID: https://orcid.org/0000-0001-5149-7385)
Institutions
- Seoul National University (KR)
- Cancer Research Institute (US)
- Seoul National University Hospital (KR)
- National University College (PR)
Publication Details
- Journal
- Cell Communication and Signaling
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1186/s12964-025-02521-4
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Research Foundation
- Seoul National University
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea